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Background

SARS-CoV-2 antibody testing shows the prevalence of COVID-19 disease in different communities and has epidemiological significance.
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Methods

SARS-CoV-2 IgM and IgG were tested in 319 patients, staff and visitors of a primary care
clinic in Las Vegas, NV on a continuous as-requested basis.
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Results

Prevalence of SARS-CoV-2 antibodies was 3.76% in a primary care office in Las Vegas, NV.
Positivity of IgM was 0.31% and IgG 3.44%. The most common symptoms reported amongst
those who tested positive were cough, shortness of breath and loss of smell and taste. The
most common comorbidities included hypertension, chronic lung disease, seasonal allergies,
and type 2 diabetes mellitus, in that order.

Conclusion

Prevalence was 2.3% in Washoe County, NV in June 2020 and 3.76% in Clark County, NV in
April–June 2020. This has important implications for heavily populated urban areas.
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Background

One priority for the Centers for Disease Control (CDC) and The US Department of Health
and Human Services (HHS) has been to track
Coronavirus Disease 2019 (COVID-19) infections to determine how much of the US population is infected over time. A variety of surveillance systems are in place to track COVID-19
cases based on those who seek medical care.
However, these systems can miss infections
that occur in people who have mild symptoms
or are asymptomatic.1,2
As of November 6th, 2020 more than 9.6 million people have been infected with the virus
in United States with 234,927 fatalities. There
have been nearly 105,360 confirmed cases and

over 1,824 deaths in Nevada.3 By using a positive
serology as the prevalence measure, we can
estimate the total number of people that have
been infected, including those infections that
might have been missed. These surveys also
can help determine how much of the population has not yet been affected, promoting
public health officials’ plans for future healthcare needs. One final benefit is that infections
can be monitored as they progress through the
population over time. This is done by taking
“snapshots” of the percentage of people who
have antibodies against Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARSCoV-2) at different time points. Our goal was
to estimate the seroprevalence of the local
population by testing patients in an outpatient
internal medicine clinic in Las Vegas, NV.4,5
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Methods

In one outpatient internal medicine setting in
Las Vegas, NV, SARS-CoV-2 testing was verbally offered by front desk staff to every single
patient, visitor, relative, staff and resident who
presented to the office from April–June 2020.
There were no exclusion criteria. Testing was
completely voluntary. Almost all people agreed
to have the test done and even volunteered
their children for the test as well. Subjects
were tested on-site, and the results were given
to them in 10–15 minutes.
Testea Biotechnology makes the test used in
Hangzhou, China. (Hangzhou Biotest Biotech
COVID-19 IgG/IgM Rapid Test Cassette Developer) (Biotest Biotech Test: COVID-19 IgG/
IgM Rapid Test Cassette) (Technology: Lateral
flow, Target: Spike). The IgG/IgM test cassette
is a qualitative membrane-based immunoassay
for the detection of IgG and IgM antibodies
in whole blood. When blood is applied to the
cartridge (pin-prick from a finger), a colored
line appears in the respective test line. This
was done by a qualified registered nurse in our
study. To serve as a procedural control, a colored line will always appear in the control line
region, indicating the proper volume of specimen has been added, and membrane wicking
has occurred. The sensitivity of the IgG result
is estimated to be at 96%, and specificity is
at 100% when compared to commercial polymerase chain reaction (PCR) testing. PCR test
have been performed by outside laboratories
for some of the cases prior to our testing. We
did not perform any corroboration separately
by virus antigen or PCR.
Descriptive statistics were used to examine the
distribution of the outcomes and predictors.
Means and standard deviation or their alternatives were computed for continuous variables
and percentages for categorical variables.

Results

Between April–June 2020, 319 tests were
administered. Subject ages ranged from 3 to
92 with a median age of 56.6. Of those tested,
1% were between 1–9 years old, 1.5% between
10-19, 4% between 20–29, 13% between 30–39,
12% between 40–49, 16% between 50–59, 19.5%
between 60–69, 18.8% between 70–79, 8.5%
between 80–89 and 2% between 90–99. The
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subjects were 166 females (52%) and 153 (48%)
males.
Of the 319 tests completed, 12 (3.76%) have
positive tests. 11 (3.44%) tested positive for IgG
antibodies, 1 (0.31%) tested positive for IgM
antibodies only, and 3 (0.94%) tested positive
for both IgG and IgM. IgG shows immunity, and
IgM shows an active infection. The combined
IgG and IgM possibly indicates a case that was
active and was getting protection at that time.6
Positive cases consisted of 4 females (33.3 %)
and 8 males (66.6 %). The youngest person
who tested positive was 44, and the oldest person was 86, with a mean age of 61 years. Four
people identified potential places that they
had been exposed to the virus, including a golf
course, a resort in Laughlin, NV, a busy grocery
store and a busy drug store. These obviously
cannot be independently confirmed. Subjects
ranged in employment history and exposure
risk.
Cases had self-reported comorbidities: 5 (41%)
were hypertensive, 3 (25%) had chronic lung
disease, and another 3 had seasonal allergies,
2 (16.6%) had diabetes and another 2 autoimmune conditions (Sjogren’s’ syndrome and
rheumatoid arthritis), 1 (8.3%) person each had
cardiovascular disease, chronic liver disease,
vitamin D deficiency or were a smoker. (Table 1)
Three positive cases were on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for hypertension.
Five people with positive IgG antibodies had
positive prior PCR testing for SARS-CoV-2 in
the previous weeks or months. Of those, 2 people had positive IgM as well. One person had
negative PCR earlier (approximately 2 weeks
ago) but a positive antibody test, and another person had a positive PCR earlier (about 3
weeks) with a current negative antibody test.
Four of the positive cases had no symptoms
(33.3%), and 9 had symptoms (66%). Symptoms lasted from 6–30 days with an average
of 10 days. Symptoms were cough in 6 (66%),
loss of smell in 4 (41%), fever in 3 (33%), loss of
taste in 3 (33%), shortness of breath in 3 (33%),
fatigue in 2 (25%), diarrhea in 2 (25%), chills in 1
(16.6) and chest discomfort in 1 (16.6%). Nobody reported rigors, runny nose, sore throat,
loss of appetite, headache, nausea or vomiting.
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Table 1. Co-morbidities in patients with a positive test.
Number of
co-morbidities

Co-morbidities
Hypertension

41%

6

One patient

COPD

25%

4

One patient

Seasonal allergies

25%

3

Two patients

Diabetes

16.6%

2

One patient

Autoimmune diseases

16.6%

1

Three patients

Cardiovascular diseases

8.3%

0

Four Patients

Vitamin D deficiency

8.3%

Chronic liver disease

8.3%

Discussion

As of November 6th, 2020, the Southern Nevada health district has reported 86,673 cases and
an upward trend. Nevada was in the red zone
for cases, indicating more than 100 new cases
per 100,000 population per week, and the red
zone for test positivity, indicating a rate above
10%. At one point in July, Nevada had 173 new
cases per 100,000 population, compared to a
national average of 119 per 100,000.7
In a study done in Reno, NV, in June 2020, the
prevalence was estimated at 2.3%. In that
study in Washoe County, 1,270 households from
within 128 unique census blocks were used and
234 people from those agreed to provide blood
samples for antibody testing.8 In contrast, our
study revealed a 3.76% prevalence in Las Vegas
during almost the same time period. This can
be the difference between a more urban area
with a less urban one or just a sign of progression and spread of the disease.
Seroprevalence studies such as this study can
be a useful asset to both the community and
state health departments, as well as the CDC.
With such surveys we can learn about the total
number of people that have been infected,
infections that might have been missed, and
assist with estimations of how much of the
population has not yet been infected. Herd immunity can be achieved on average if more than
60–70 percent of the population have been exposed.9 Cases in Las Vegas have declined since
peaking in mid-July. There has been a move
toward community-led neighborhood testing.
Surge testing and contact tracing resources
have been allocated to neighborhoods and zip
codes with the highest case rates. Laboratory
turnaround times have decreased from many
days to 2–3 days in several states like AZ.10

Results can help identify areas where to more
aggressively implement community mitigation
strategies. Community-level estimates can
complement case-based and syndromic surveillance as a tool to understand local transmission
and the extent of past infection in a population.
The relatively low seroprevalence estimate in
this report suggests that most persons in the
catchment area had not been infected with
SARS-CoV-2 by early October. There has been
a relative paucity of community-based studies conducted but their utility may increase as
planned phases of re-opening progress.

Limitations

One limitation of our study was the testing
bias. We performed the test by consent and
acceptance of subjects and did not test all in
a blinded fashion. Timing of the test in April–
June might also have an effect on the overall
results. We assumed 100% accuracy for our
test (the sensitivity was actually reported at
96% for the test) and no confirmatory tests
were done to corroborate for false positives or
false negatives. Also the positive antibody tests
results were limited, which makes drawing a
definitive conclusion a bit difficult.
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